SCHEMBL778770

SCHEMBL778770

Cc1ccc(-c2ccccc2)c(F)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.50
PTGS1 P23219 3/20 0.50
MEN1 O00255 3/20 0.50
KMT2A Q03164 3/20 0.50
MAPT P10636 3/20 0.50
PTGS2 P35354 2/20 0.50
AKR1C3 P42330 2/20 0.50
AKR1C2 P52895 2/20 0.50
FABP2 P12104 1/20 0.50
TSHR P16473 1/20 0.50
AKR1C4 P17516 1/20 0.50
ADRA2B P18089 1/20 0.50
CHRM3 P20309 1/20 0.50
HTR2C P28335 1/20 0.50
DRD3 P35462 1/20 0.50
AKR1C1 Q04828 1/20 0.50
SLC22A6 Q4U2R8 1/20 0.50
CYP1A2 P05177 1/20 0.50
CYP2C9 P11712 1/20 0.50
HPGD P15428 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29763737 1.00 LMNA (0.50) LMNAPTGS1MEN1KMT2AMAPT
SCHEMBL13967517 0.89 PTGS2 (0.46) LMNAPTGS1MEN1KMT2AMAPT
SCHEMBL10018702 0.86 PTGS2 (0.48) LMNAPTGS1MAPTPTGS2AKR1C3
SCHEMBL10091190 0.86 MAPT (0.49) LMNAPTGS1MEN1KMT2AMAPT
SCHEMBL10091182 0.86 MAPT (0.49) LMNAPTGS1MEN1KMT2AMAPT
SCHEMBL9228338 0.85 GRM2 (0.42) LMNAPTGS1MEN1KMT2AMAPT
SCHEMBL10013948 0.84 PTGS2 (0.47) LMNAPTGS1MAPTPTGS2AKR1C3
SCHEMBL257801 0.83 ACHE (0.50) PTGS1MEN1KMT2APTGS2CYP2C9
SCHEMBL29893393 0.83 HDAC7 (0.47) LMNAPTGS1MEN1KMT2AMAPT
SCHEMBL13220237 0.83 HDAC7 (0.47) LMNAPTGS1MEN1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 131 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1667958-A2 MELANIN CONCENTRATING HORMONE ANTAGONISTS THE PROCTER & GAMBLE COMPANY (US) 2006-06-14 EP claimed
WO-2005033063-A2 MELANIN CONCENTRATING HORMONE ANTAGONISTS THE PROCTER & GAMBLE COMPANY (US) 2005-04-14 WO claimed
US-20050075324-A1 Melanin concentrating hormone antagonists THE PROCTER & GAMBLE COMPANY (US) 2005-04-07 US claimed
US-4422979-A Fluoro-substituted biphenylyl compounds and processes ETHYL CORPORATION (US) 1983-12-27 US claimed
US-4371473-A Preparation of 2-(2-fluoro-4-biphenylyl)propionic acid and corresponding nitride ETHYL CORPORATION (US) 1983-02-01 US claimed
US-4278516-A Method for the preparation of 2-fluoro-4-monobromomethylbiphenyl ETHYL CORPORATION (US) 1981-07-14 US claimed
JP-57009757-A None JP disclosed
JP-57045151-A None JP disclosed
JP-55157530-A None JP disclosed
JP-55157523-A None JP disclosed
CN-115322070-A Preparation method of p-alkyl phenyl o-fluorobenzene 烟台盛华液晶材料有限公司 2022-11-11 CN disclosed
US-11387414-B2 Spirobifluorene compounds for organic electroluminescent devices MERCK PATENT GMBH (DE) 2022-07-12 US disclosed
US-11236082-B2 EZH2 inhibitors and uses thereof DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-02-01 US disclosed
US-4371473-A Preparation of 2-(2-fluoro-4-biphenylyl)propionic acid and corresponding nitride ETHYL CORPORATION (US) 1983-02-01 US disclosed
JP-S5745151-A ALPHA-SULFONYL 2-FLUORO-4-BIPHENYLYL PROPIONIC ACID DERIVATIVE SAGAMI CHEM RES CENTER 1982-03-13 JP disclosed
JP-S579757-A ALPHA-SULFONYL 2-FLUORO-4-BIPHENYLYL ACETIC ACID DERIVATIVE SAGAMI CHEM RES CENTER 1982-01-19 JP disclosed
US-4278516-A Method for the preparation of 2-fluoro-4-monobromomethylbiphenyl ETHYL CORPORATION (US) 1981-07-14 US disclosed
US-4278516-A Method for the preparation of 2-fluoro-4-monobromomethylbiphenyl ETHYL CORPORATION (US) 1981-07-14 US disclosed
JP-S55157530-A PREPARATION OF 3-FLUORO-4-PHENYLBENZALDEHYDE SAGAMI CHEM RES CENTER 1980-12-08 JP disclosed
JP-S55157523-A HALOGENATED 3-FLUORO-4-PHENYLBENZAL SAGAMI CHEM RES CENTER 1980-12-08 JP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075324-A1 Melanin concentrating hormone antagonists MCHR1, MCHR2, MC1R LMNA 4834/4885PTGS1 2265/4885MEN1 238/4885
US-11387414-B2 Spirobifluorene compounds for organic electroluminescent devices PKD1, PIEZO1, AQP1 LMNA 3591/4885PTGS1 1288/4885MEN1 500/4885
US-11236082-B2 EZH2 inhibitors and uses thereof EZH2, EZH1, BMI1 LMNA 2203/4885PTGS1 2734/4885MEN1 1860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.